Zymes, Kaneka sign agreement
This article was originally published in The Tan Sheet
Executive Summary
Hasbrouck Heights, N.J.-based bioscience firm Zymes announces Nov. 3 it signed an "exclusive co-development co-marketing agreement" with Osaka, Japan-based Kaneka Nutrients L.P. The agreement pertains to Kaneka's water-soluble liquid and powder Kaneka QH (Ubiquinol) that uses Zymes' "nanotechnology and complexation to formulate and improve solubility of water-insoluble bioactives." The firms will co-market PTS/Kaneka QH for use in food, beverages and supplements in North America, Zymes' release says
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.